

entering into Stip. of Fact 4-21 the Respondent accepted responsibility for his recordkeeping violations that occurred in his practice prior to February 2014, as alleged in paragraph 4 of the OSC. FF 24. This limited acceptance of responsibility is outweighed by his numerous prescribing and dispensing transgressions, for which he has not accepted responsibility.³² See *Hatem M. Ataya, M.D.*, 81 Fed. Reg. 8221, 8244 (2016) (“[T]here are cases in which, notwithstanding a finding that a registrant has credibly accepted responsibility, the misconduct is so egregious and extensive that the protection of the public interest nonetheless warrants the revocation of a registration or the denial of an application.”).

When considering whether the Respondent’s continued registration is consistent with the public interest, the ALJ must consider both the egregiousness of the registrant’s violations and the DEA’s interest in deterring future misconduct by both the registrant as well as other registrants. *David A. Ruben, M.D.*, 78 Fed. Reg. 38363, 38364 (2013); see also *Richard J. Settles, D.O.*, 81 Fed. Reg. 64940, 64945 n.17 (2016) (“In short, this is not a contest in which score is kept; the Agency is not required to mechanically count up the factors and determine how many favor the Government and how many favor the registrant. Rather, it is an inquiry which focuses on protecting the public interest; what matters is the seriousness of the registrant’s misconduct.” (quoting *Jayam Krishna-Iyer, M.D.*, 74 Fed. Reg. 459, 462 (2009)). While I do not believe that the Respondent’s transgressions rise to the level of intentional or knowing diversion, I do find his multiple and repeated recordkeeping and prescribing violations to be sufficiently egregious to warrant revocation.³³ See *Dewey C.*

Administrator to draw an adverse inference from [the Respondent’s] failure to testify”). I note, however, that even absent the adverse inference, there is sufficient evidence to support the conclusion that the Respondent has not accepted responsibility for his improper prescribing and dispensing of controlled substances.

³² Although the Respondent also stipulated to many of the facts underlying the allegations contained in paragraphs 7 and 9 of the OSC, those stipulations do not admit to any misconduct. They just admit to facts. The essence of the allegations contained in paragraphs 7 and 9 of the OSC is that the Respondent’s actions involving controlled substances were outside the course of professional practice and furthered no legitimate medical purposes.

³³ I acknowledge that the Respondent has taken some remedial steps to reduce the likelihood that his actions would result in future violations of the CSA and/or its implementing regulations. Nevertheless, a registrant does not accept

MacKay, M.D., 75 Fed. Reg. 49956, 49974 n.35 (2010) (“[U]nder the public interest standard, DEA has authority to consider those prescribing practices of a physician, which, while not rising to the level of intentional or knowing misconduct, nonetheless create a substantial risk of diversion.”).

RECOMMENDATION

The Government established that the Respondent’s continued registration is inconsistent with the public interest because of his improper recordkeeping and improper prescribing, and/or dispensing, of controlled substances to himself, his family, and his patients. While the Respondent admitted to many of the Government’s factual allegations, he failed to fully accept responsibility and acknowledge that his egregious actions fell below the standard of care in the State of Connecticut, and/or lacked any legitimate medical purpose. Accordingly, I **RECOMMEND** that the Respondent’s DEA COR be **REVOKED** and that any application for renewal of his registration be **DENIED**.

Dated: May 25, 2017
s/Charles Wm. Dorman
U.S. Administrative Law Judge

CERTIFICATE OF SERVICE

This is to certify that the undersigned, on May 25, 2017, caused a copy of the foregoing to be transmitted via facsimile and placed in interoffice mail addressed to Paul A. Dean, Esq., Office of Chief Counsel, Drug Enforcement Administration, 8701 Morrisette Drive, Springfield, VA 22152; facsimile (202) 307-4946, and a copy to be transmitted via facsimile and mailed, postage prepaid, to counsel for the Respondent, Ronald W. Chapman, II, Esq. and Robert J. Andretz, Esq., 1441 West Long Lake Road, Suite 310, Troy, Michigan 48098; facsimile (248) 644-6324.

Rhonda L. Gore
Secretary to Judge Charles Wm. Dorman
Office of Administrative Law Judges

[FR Doc. 2019-02865 Filed 2-20-19; 8:45 am]

BILLING CODE 4410-09-P

responsibility for its actions simply by taking remedial measures. *Holiday CVS, L.L.C., d/b/a CVS/Pharmacy Nos. 219 & 5195*, 77 Fed. Reg. 62316, 62346 (2012). Further, where a registrant has not accepted responsibility it is not necessary to consider evidence of the registrant’s remedial measures. *Jones Total Health Care Pharmacy, L.L.C. & SND Health Care, L.L.C.*, 81 Fed. Reg. 79188, 79202-03 (2016).

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Navinta LLC

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 22, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been delegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on September 13, 2018, Navinta, LLC., 1499 Lower Ferry Road, Ewing, New Jersey 08618-1414 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Pentobarbital	2270	II
4-Anilino-N-phenethyl-4-piperidine (ANPP).	8333	II
Levorphanol	9220	II
Remifentanil	9739	II
Fentanyl	9801	II

The company plans to manufacture the listed controlled substances in bulk for sale to its customers.

Dated: February 11, 2019.

John J. Martin,

Assistant Administrator.

[FR Doc. 2019-02877 Filed 2-20-19; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Noramco, Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 22, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on October 30, 2018, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Marihuana	7360	I
Tetrahydrocannabinols.	7370	I
Codeine-N-oxide	9053	I
Dihydromorphine	9145	I
Hydromorphinol	9301	I
Morphine-N-oxide	9307	I
Amphetamine	1100	II

Controlled substance	Drug code	Schedule
Methylphenidate	1724	II
Nabilone	7379	II
Phenylacetone	8501	II
Codeine	9050	II
Dihydrocodeine	9120	II
Oxycodone	9143	II
Hydromorphone	9150	II
Hydrocodone	9193	II
Morphine	9300	II
Oripavine	9330	II
Thebaine	9333	II
Opium extracts	9610	II
Opium fluid extract ...	9620	II
Opium tincture	9630	II
Opium, powdered	9639	II
Opium, granulated	9640	II
Oxymorphone	9652	II
Noroxymorphone	9668	II
Tapentadol	9780	II

The company plans to manufacture bulk active pharmaceutical ingredients (APIs) and reference standards for distribution to their customers.

In reference to drug codes 7360 (marihuana) and 7370 (tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetics. No other activities for these drug codes are authorized for this registration.

Dated: February 11, 2019.

John J. Martin,

Assistant Administrator.

[FR Doc. 2019-02883 Filed 2-20-19; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Stepan Company

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 25, 2019. Such persons may also file a written request for a hearing on the application on or before March 25, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his

authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on December 7, 2018, Stepan Company, 100 W Hunter Ave, Maywood, New Jersey 07607, re-applied to be registered as a bulk manufacturer of the following basic classes of controlled substances.

Controlled substance	Drug code	Schedule
Cocaine	9041	II
Ecgonine	9180	II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Dated: February 11, 2019.

John J. Martin,

Assistant Administrator.

[FR Doc. 2019-02878 Filed 2-20-19; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: The registrant listed below has applied for and been granted registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of various classes of schedule I and II controlled substances.

SUPPLEMENTARY INFORMATION: The company listed below applied to be registered as a bulk manufacturer of various basic classes of controlled substances. Information on a previously published notice is listed below. No comments or objections were submitted for the notice.